|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
101.95(B) |
Last
Volume: |
351,356 |
Avg
Vol: |
769,142 |
52
Week Range: |
$692.45 - $993.35 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
24,729 |
84,192 |
120,701 |
282,978 |
Total Sell Value |
$23,631,267 |
$76,701,012 |
$107,160,703 |
$220,505,683 |
Total People Sold |
7 |
13 |
15 |
17 |
Total Sell Transactions |
14 |
38 |
55 |
116 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Stahl Neil |
EVP Research and Development |
|
2021-12-11 |
4 |
D |
$664.34 |
$500,248 |
D/D |
(753) |
53,130 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2021-12-10 |
4 |
D |
$664.34 |
$919,447 |
D/D |
(1,384) |
30,073 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2021-12-10 |
4 |
OE |
$555.67 |
$833,505 |
D/D |
1,500 |
31,457 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2021-12-10 |
4 |
AS |
$656.46 |
$520,477 |
D/D |
(781) |
29,957 |
|
3% |
|
Murphy Andrew J |
EVP Research |
|
2021-12-10 |
4 |
AS |
$657.61 |
$4,745,202 |
D/D |
(7,122) |
59,167 |
|
3% |
|
Tessier-Lavigne Marc |
Director |
|
2021-12-09 |
4 |
AS |
$665.00 |
$2,516,360 |
D/D |
(3,784) |
2,078 |
|
6% |
|
Tessier-Lavigne Marc |
Director |
|
2021-12-09 |
4 |
OE |
$371.40 |
$1,405,378 |
D/D |
3,784 |
5,862 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2021-12-09 |
4 |
D |
$657.11 |
$2,279,515 |
D/D |
(3,469) |
30,738 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2021-12-09 |
4 |
OE |
$399.66 |
$1,698,555 |
D/D |
4,250 |
34,207 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2021-12-09 |
4 |
D |
$657.11 |
$12,992,379 |
D/D |
(19,772) |
26,748 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2021-12-09 |
4 |
OE |
$179.13 |
$5,373,900 |
D/D |
30,000 |
46,520 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2021-12-09 |
4 |
D |
$657.11 |
$6,162,378 |
D/D |
(9,378) |
66,289 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2021-12-09 |
4 |
OE |
$52.03 |
$858,495 |
D/D |
16,500 |
75,667 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,338 |
20,376 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
4,344 |
31,275 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,971 |
29,957 |
|
- |
|
Fenimore Christopher R. |
SVP Controller |
|
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,859 |
21,392 |
|
- |
|
Vagelos P Roy |
Director |
|
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,861 |
318,669 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,338 |
16,520 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,462 |
59,167 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,926 |
53,883 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2021-12-03 |
4 |
D |
$632.45 |
$31,845,122 |
D/D |
(50,352) |
50,957 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2021-12-03 |
4 |
OE |
$179.13 |
$12,986,925 |
D/D |
72,500 |
101,309 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2021-11-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,605 |
4,605 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2021-11-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,605 |
28,809 |
|
- |
|
1366 Records found
|
|
Page 18 of 55 |
|
|